The PFAS proposal: what is it, and where does it stand?
EU law increasingly regulates the use of PFAS, the so-called "forever chemicals". For MedTech and pharma companies, the implications are significant and some restrictions already apply.
Explore our latest insights, regulatory updates, and strategic reports for the life sciences sector.
16 results
EU law increasingly regulates the use of PFAS, the so-called "forever chemicals". For MedTech and pharma companies, the implications are significant and some restrictions already apply.
Axon assisted a cosmetics company facing enforcement by the Dutch Food and Consumer Product Authority NVWA re. the sample service it operated. Axon advised the company on the applicable CPNP notification and labelling requirements, based on which the company could ensure compliance.
Our team has trained several multinationals on the implications of the Battery Regulation and the Packaging & Packaging Waste regulation, and regularly advises on these topics.
We have assisted a medical device manufacturer in ensuring that their SAAS-application complies with the Data Act and the GDPR.
We have advised several clients on the classification of their medical devices, including software products, under the MDR and IVDR, and have helped them in negotiating.
Our team advised a client on the registration process under REACH.
We have advised a start-up on the legal limitations and requirements related to the transport of dangerous substances.
We have advised a medical device manufacturer on the regulatory implications of the restriction on synthetic polymer microparticles for its products.
We have assisted a distributor of medical devices on questions pertaining to a cleaning solution regulated under the Biocidal Product Regulation.
Our team assisted a mid-sized cosmetics company with the negotiation of a distribution agreement.